Next report date
Report period
Q1 2024
EPS estimate
−0.02EUR
Revenue estimate
463.39 KEUR
−0.09EUR
−42.14 MEUR
1.30 MEUR
466.31 M
About Perspective Therapeutics, Inc.
Sector
Industry
CEO
Johan M. Spoor
Website
Headquarters
Seattle
Employees (FY)
119
Founded
1998
Perspective Therapeutics, Inc. is a medical technology and radiopharmaceutical company, which engages in the provision of treatment applications for cancers. The company was founded in 1998 and is headquartered in Seattle, WA.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of AAJ is 1.50 EUR — it has increased by 2.04% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on GETTEX exchange PERSPECTIVE THERAPEUTICS INC stocks are traded under the ticker AAJ.
PERSPECTIVE THERAPEUTICS INC is going to release the next earnings report on May 14, 2024. Keep track of upcoming events with our Earnings Calendar.
AAJ stock is 4.17% volatile and has beta coefficient of −0.08. Check out the list of the most volatile stocks — is PERSPECTIVE THERAPEUTICS INC there?
AAJ earnings for the last quarter are −0.04 EUR per share, whereas the estimation was −0.04 EUR resulting in a 11.11% surprise. The estimated earnings for the next quarter are −0.03 EUR per share. See more details about PERSPECTIVE THERAPEUTICS INC earnings.
PERSPECTIVE THERAPEUTICS INC revenue for the last quarter amounts to 1.81 M EUR despite the estimated figure of 1.75 M EUR. In the next quarter revenue is expected to reach 1.63 M EUR.
Yes, you can track PERSPECTIVE THERAPEUTICS INC financials in yearly and quarterly reports right on TradingView.
AAJ stock has risen by 10.29% compared to the previous week, the month change is a 30.43% rise, over the last year PERSPECTIVE THERAPEUTICS INC has showed a 183.02% increase.
AAJ net income for the last quarter is −9.80 M EUR, while the quarter before that showed −10.18 M EUR of net income which accounts for 3.78% change. Track more PERSPECTIVE THERAPEUTICS INC financial stats to get the full picture.
Today PERSPECTIVE THERAPEUTICS INC has the market capitalization of 875.42 M, it has increased by 4.47% over the last week.
No, AAJ doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, AAJ shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade PERSPECTIVE THERAPEUTICS INC stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 26, 2024, the company has 119.00 employees. See our rating of the largest employees — is PERSPECTIVE THERAPEUTICS INC on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So PERSPECTIVE THERAPEUTICS INC technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating PERSPECTIVE THERAPEUTICS INC stock shows the strong buy signal. See more of PERSPECTIVE THERAPEUTICS INC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on PERSPECTIVE THERAPEUTICS INC future price: according to them, AAJ price has a max estimate of 1.84 EUR and a min estimate of 1.38 EUR. Read a more detailed PERSPECTIVE THERAPEUTICS INC forecast: see what analysts think of PERSPECTIVE THERAPEUTICS INC and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. PERSPECTIVE THERAPEUTICS INC EBITDA is −28.21 M EUR, and current EBITDA margin is −2.78 K%. See more stats in PERSPECTIVE THERAPEUTICS INC financial statements.